Geometrical Comparison and Quantitative Evaluation of $^{18}$F-FDG PET/CT- and DW-MRI-Based Target Delineation Before and During Radiotherapy for Esophageal Squamous Carcinoma

Huimin Li$^{1,2}$, Jianbin Li$^3$*, Fengxiang Li$^3$*, Yingjie Zhang$^3$, Yankang Li$^3$, Yanluan Guo$^4$ and Liang Xu$^5$

$^1$ Weifang Medical University, Weifang, China, $^2$ Department of Respiratory and Neurology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China, $^3$ Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, $^4$ Department of Positron Emission Tomography-Computed Tomograph (PET-CT), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, $^5$ Department of Medical Imaging, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

**Background and Purpose:** This study aimed to evaluate the geometrical differences in and metabolic parameters of $^{18}$F-fluorodeoxyglucose positron emission tomography–computed tomography ($^{18}$F-FDG PET-CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) performed before and during radiotherapy (RT) for patients with esophageal cancer based on the three-dimensional CT (3DCT) medium and explore whether the high signal area derived from DW-MRI can be used as a tool for an individualized definition of the volume in need of dose escalation for esophageal squamous cancer.

**Materials and Methods:** Thirty-two patients with esophageal squamous cancer sequentially underwent repeated 3DCT, $^{18}$F-FDG PET-CT, and enhanced MRI before the initiation of RT and after the 15th fraction. All images were fused with 3DCT images through deformable registration. The gross tumor volume (GTV) was delineated based on PET Edge on the first and second PET-CT images and defined as GTV$_{PETpre}$ and GTV$_{PETdur}$, respectively. GTV$_{DWIpre}$ and GTV$_{DWIdur}$ were delineated on the first and second DWI and corresponding T$_2$-weighted MRI (T$_2$W-MRI)-fused images. The maximum, mean, and peak standardized uptake values (SUVs; SUV$_{max}$, SUV$_{mean}$, and SUV$_{peak}$, respectively); metabolic tumor volume (MTV); and total lesion glycolysis (TLG) and its relative changes were calculated automatically on PET. Similarly, the minimum and mean apparent diffusion coefficient (ADC; ADC$_{min}$ and ADC$_{mean}$) and its relative changes were measured manually using ADC maps.
Results: The volume of GTV_{CT} exhibited a significant positive correlation with that of GTV_{PET} and GTV_{DWI} (both \( p < 0.001 \)). Significant differences were observed in both ADCs and \(^{18}\text{F}-\text{FDG}\) PET metabolic parameters before and during RT (both \( p < 0.001 \)). No significant correlation was observed between SUVs and ADCs before and during RT (\( p = 0.072–0.944 \)) and between \( \Delta \text{ADCs} \) and \( \Delta \text{SUVs} \) (\( p = 0.238–0.854 \)). The conformity index and degree of inclusion of GTV_{PET\text{pre}} to GTV_{DWI\text{pre}} were significantly higher than those of GTV_{PET\text{dur}} to GTV_{DWI\text{dur}} (both \( p < 0.001 \)). The maximum diameter shrinkage rate (\( \Delta \text{LD}_{\text{DWI}} \) (24%)) and the tumor volume shrinkage rate (VRR_{DWI}) (60%) based on DW-MRI during RT were significantly greater than the corresponding PET-based \( \Delta \text{LD}_{\text{PET}} \) (14%) and VRR_{PET} (41%) rates (\( p = 0.017 \) and 0.000, respectively).

Conclusion: Based on the medium of CT images, there are significant differences in spatial position, biometabolic characteristics, and the tumor shrinkage rate for GTVs derived from \(^{18}\text{F}-\text{FDG}\) PET-CT and DW-MRI before and during RT for esophageal squamous cancer. Further studies are needed to determine if DW-MRI will be used as tool for an individualized definition of the volume in need of dose escalation.

Keywords: esophageal squamous carcinoma, diffusion magnetic resonance imaging, positron emission tomography, gross target volume, standard uptake value (SUV), apparent diffusion coefficient (ADC)

INTRODUCTION

Radiotherapy—one of the main effective and relatively safe treatment modalities—is now fully integrated in the multidisciplinary treatment of esophageal cancer (EC). Currently, with substantial evidence, radiotherapy can be applied as a sole treatment or as part of a comprehensive treatment in combination with systemic treatments such as surgery, chemotherapy, targeted therapy, and, more recently, immunotherapy (1). Regional recurrence accounts for most radiation treatment failures in EC cases, with a local relapse rate of 40% (2). In particular, 90% of locoregional failures after definitive chemoradiotherapy (dCRT) occurred within the gross tumor volume (GTV) (3). Hence, there is an urgent need to escalate the radiation dose to the area at highest risk of recurrence to improve locoregional control. Currently, there is a growing interest in the delivery of intensity-modulated radiotherapy (IMRT)-based late course boost or simultaneously integrated boost techniques (4, 5), which could selectively deliver high radiation doses to radioresistant regions and a relatively low dose to subclinical tissues.

Currently, metabolic and functional imaging modalities such as \(^{18}\text{F}-\text{fluorodeoxyglucose}\) positron emission tomography–computed tomography (\(^{18}\text{F}-\text{FDG}\) PET-CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) are gaining increasing clinical significance in the management of patients undergoing radiotherapy since these allow visualization and quantification of treatment-induced changes on a molecular level before volumetric changes become apparent (6–8). It is well known that PET-based parameters such as standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) have been established and validated as prognostic biomarkers in EC (8, 9). Escalating the radiation dose to 64.8 Gy, which had been previously established, failed to improve survival or locoregional control (10). It is warranted to explore potential tools for an individualized definition of the volume in need of dose escalation. The current analysis demonstrates that high FDG uptake on initial PET-CT can identify tumor areas at high risk of relapse in EC (9, 11). Another study by Yu et al. (5) showed that the FDG hotspot within the residual area was completely within the GTV and remained stable during RT. They also reported that adaptive RT based on target volume reduction assessed on PET-CT could facilitate dose escalation up to 70 Gy, with a 1-year overall survival and local control of 69.2% and 77.4%, respectively. Therefore, it is feasible and safe to select boosting of high \(^{18}\text{F}-\text{FDG}\) uptake zones within the tumor based on FDG PET-CT for the definition of the volume in need of dose escalation.

However, repeated PET imaging has not been widely adopted regardless of its clinical benefit owing to radiation exposure and uncertain segmentation algorithms obtained during PET (12, 13). In contrast, considering patient acceptability, repeated MRI is generally well tolerated for response assessment (14). High-resolution MRI for target volume delineation and response assessment in EC is currently of immense clinical interest (15, 16). The apparent diffusion coefficient (ADC) map from DW-MRI is a quantitative measure for the motion of water molecules and inversely correlates with tissue density. Relevant studies have shown that lower ADC values were associated with a higher histological grade and aggressiveness (17). Furthermore, it has been recently recognized that relative ADC changes from baseline to interim DW-MRI scans can help identify pathologic response in EC patients (7). Hence, we could theoretically observe the feasibility of selective boosting of the high signal areas of EC based on DW-MRI for definition of the volume in need of dose escalation.
Currently, selective boosting of high 18F-FDG uptake zones based on FDG PET-CT within the tumor has been suggested for radiosistance (5, 9, 11). To date, CT imaging of the tumor extension remains the gold standard for target volume contouring and plan evaluation. Therefore, based on the medium of CT images, we evaluated the spatial position and functional parameters of 18F-FDG PET-CT and DW-MRI performed before and during radiotherapy in patients with esophageal squamous carcinoma. The aim of this study was to explore whether the high signal area derived from DW-MRI can be used as tool for an individualized definition of the volume in need of dose escalation for esophageal squamous cancer.

MATERIALS AND METHODS

Patient Selection and Characteristics

After receiving approval from the local research ethics committee, a total of 35 patients with newly diagnosed, biopsy-proven, nonmetastatic esophageal squamous carcinoma suitable for concurrent chemoradiotherapy were recruited for this prospective study between November 2016 and May 2020. All patients scheduled to receive neoadjuvant or definitive chemoradiotherapy for EC underwent 3DCT, 18F-FDG PET-CT, and MRI simulation scanning prior to the initiation of RT and after 15 fractions of RT. Written informed consent was obtained from every patient included in this study. Patients were excluded if either pre-RT 18F-FDG PET-CT or DW-MRI data were not available (n = 1), the volume of the tumor on baseline metabolic imaging was extremely small (≤ 1 cm³) (n = 1), or they did not complete RT (n = 1). Consequently, image data of 32 patients were available for analysis. Patient and treatment characteristics are presented in Table 1.

Image Simulation and Acquisition

Each patient underwent contrast-enhanced CT using a 16-slice CT scanner (Philips Brilliance Boreas CT, Cleveland, OH, USA), with a 3-mm slice thickness during free breathing. All patients were scanned in the supine position, followed by laser alignment. The 18F-FDG PET-CT examinations were performed within 2 weeks before the initiation of RT (PETpre) and after 15 fractions (median 27 Gy, 1.8 Gy per fraction) of RT (PETdur). Following CT, PETpre was performed from the proximal thigh to the base of the skull in 3D acquisition mode with 2–5 min per bed position, while PETdur was acquired from the skull base to the diaphragm. PET images were reconstructed using iterative 3D reconstruction.

Patients underwent MRI scanning with anatomical (T2-weighted) and functional (diffusion-weighted) MRI sequences at the same two time points as that for 18F-FDG PET-CT. MRI examinations were performed on a 3.0-T scanner equipped with a 32-tunnel body phased-array coil (Discovery MR 750, GE Medical Systems, Milwaukee, WI, USA). Patients were scanned in the supine position, with arms parallel to the body for both pre- and mid-RT scanning. Transverse DW images were obtained under free breathing conditions with the following scan parameters: repetition time (TR) 13,333 ms, echo time (TE) 64 ms, acquisition matrix 128 × 128 mm, field of view (FOV) 500 × 500 mm, slice thickness = 3.6 mm, and NE = 5. A diffusion-sensitive gradient -value of 600 s/mm² was applied for DWI. T2W-MRI adopts fast spin echo to scan cross and axial sections, with the following specific parameters: TR 12,000 ms, TE 84 ms, thickness and spacing 3 mm, FOV 500 × 500 mm, acquisition matrix 384 × 384, and NE = 1.8. Additionally, conventional T2W-MR images were obtained using pulse and respiratory gating techniques to trigger scanning exclusively during the end of expiration (18).

Image Registration and Target Delineation

The 18F-FDG PET-CT and MR images were registered to the planning CT using deformable image registration (DIR) in the software MIM Vista® (MIM Software Inc., version 6.8.3,

| TABLE 1 | Patient and treatment characteristics. |
|----------|----------------------------------------|
| Patient characteristics | Number | Percent |
| Age (year), median (range) | 67 | (47–76) |
| Sex | | |
| Female | 6 | 18.8 |
| Male | 26 | 81.3 |
| ECOG PS | | |
| 0–1 | 32 | 100.0 |
| 2 | 0 | 0.0 |
| Pathology | | |
| Squamous cell carcinoma | 32 | 100.0 |
| Adenocarcinoma | 0 | 0.0 |
| Site | | |
| Upper thoracic (UI 20–25 cm) | 12 | 37.5 |
| Middle thoracic (UI 25–30 cm) | 11 | 33.4 |
| Lower thoracic (UI 30–40 cm) | 9 | 28.1 |
| Stage | | |
| II | 3 | 9.3 |
| IIIA | 4 | 12.5 |
| IIIB | 23 | 71.9 |
| IV | 3 | 9.3 |
| Treatment characteristics | | |
| Aim | | |
| Definitive chemoradiation | 28 | 87.5 |
| Neoadjuvant chemoradiation | 4 | 12.5 |
| Chemotherapy regimen | | |
| 5-Fluorouracil-cisplatin | 30 | 93.8 |
| 5-Fluorouracil monotherapy | 2 | 6.2 |
| RT modality | | |
| IMRT | 32 | 100.0 |
| 3D-CRT | 0 | 0.0 |
| Total dose (Gy), median (range) | 60 | (41.4–60) |
| Fraction dose (Gy), median (range) | 2.0 | (1.8–2.0) |
| Fractions of RT completed before midradiotherapy | 15 | 100.00 |
| PET/DWI (fractions) | | |
| Dose of RT completed before midradiotherapy | 30 | (27.30) |
| PET/DWI (Gy), median (range) | | |
| ECOG, PS Eastern Cooperative Oncology Group performance status; UI, upper incisor; RT, radiotherapy; IMRT, intensity-modulated radiotherapy; 3D-CRT, 3-dimensional conformal radiotherapy. |
| aAmerican Joint Committee on Cancer classification 2017. |
| bClinical tumor-node-metastasis (cTNM) stage according to 8th edition TNM classification. |
Cleveland, OH, USA). The main role of DIR is to define spatial correspondence between two considered image sets. To ensure the accuracy and repeatability of the delineation of target volumes, all structures were delineated by the same experienced radiation oncologist according to the consensus guidelines. GTVs were manually contoured on the first and second planning CT images, referred to as GTV_{CT}^{pre} and GTV_{CT}^{dur}, with a mediastinal window (window width = 400 HU, window level = 40 HU) setting and by the following standards: the GTVs were defined as any enlargement of the esophagus over its standard dimensions, 5 mm for wall thickness and 10 mm for wall diameter. On the basis of the reconstructed 18F-FDG PET-CT image, given that no single absolute and relative methods of PET-based target volume delineation were validated, a gradient-based segmentation algorithm (PETEdge) was applied, which identified tumors on the basis of changes in intensity/activity concentration at the tumor borders (19). The GTVs based on the first and second PET-CT images were determined using thresholds of PET_{Edge} and defined as GTV_{PET}^{pre} and GTV_{PET}^{dur}, respectively. All noncancerous regions within the GTV_{PET}, including areas overlaid by the heart, bone, and great vessels, were corrected to be excluded manually with the help of the CT component of PET-CT. Similarly, GTV_{DWI}^{pre} and GTV_{DWI}^{dur} were delineated on the first and second DWI and corresponding {T}_{2}-weighted MRI-fused images.

**Functional Parameter Extraction**

Images were analyzed and measured by two observers (a senior radiologist and an imaging physician in diagnostic PET/MRI) who were blinded to the histopathological results. Regions of interest (ROIs) were automatically drawn on the first and second PET based on PET_{Edge} and were modified to exclude any overlap with the heart, bone, and great vessels on CT images of PET-CT. The maximum, mean, and peak standardized uptake values (SUV_{max}, SUV_{mean}, and SUV_{peak}, respectively), MTV, and TLG were calculated automatically using the MIM software. TLG is defined as MTV from PET multiplied by SUV mean within that volume (20).

For ADC measurements, an ADC map in grayscale was automatically generated in DW-MRI using ADW 4.7 Workstation (GE Healthcare, Waukesha, WI, USA). The manifested largest and clearest sections of esophageal lesions were selected as the ROIs. Subsequently, ROIs on the DWI and corresponding {T}_{2}-weighted MRI fused images were edited manually by two physicians in consensus to ensure that areas of hemorrhage, necrosis, edema, cystic change, and normal vessels were excluded. Finally, through the MIM software, the positions of ROIs on the ADC map were set to the same layers and locations prior to RT and after the 15th treatment cycle. The mean and minimum ADCs (ADC_{mean} and ADC_{min}, respectively) of the lesion were automatically calculated. The relative changes in percent (Δ%) of these 18F-FDG PET-CT and DW-MRI parameters (i.e., ΔADCs, ΔSUVs, ΔMTV, and ΔTLG) between baseline scans and scans during RT were calculated.

**Overlap Analysis**

To quantify the overlap between PET-CT- and DW-MRI-based delineations before and during RT, the conformity index (CI) and degree of inclusion (DI) were calculated for GTV_{PET}^{pre} and GTV_{DWI}^{pre} and GTV_{PET}^{dur} and GTV_{DWI}^{dur}, respectively. The CI of volume A and B (CI[A, B]) was computed according to that described in a study by Struikmans et al. (21). A CI of 1 indicates 100% agreement between GTVs, and a CI of 0 indicates no overlap in delineation. The formula was as follows:

$$CI(A, B) = \frac{A \cap B}{A \cup B}$$

The definition of DI of volume A included in volume B (DI[A in B]) was the intersection between volume A and volume B divided by volume A (22). The DI was defined as follows:

$$DI(A \text{ in } B) = \frac{A \cap B}{A}$$

**Tumor Shrinkage Analysis**

Based on the Response Evaluation Criteria in Solid Tumors version 1.1, measurements of tumor volume and tumor maximal diameters were performed on PET-CT or MR images prior to and during RT. Four diameters measured on the first and second PET and DWI images were defined as LD_{PET}^{pre} and LD_{PET}^{dur} and LD_{DWI}^{pre} and LD_{DWI}^{dur}, respectively. The percentage maximum diameter shrinkage rate (ΔLD) was calculated using the following equation:

$$\DeltaLD = \frac{[LD_{pre} - LD_{dur}]}{LD_{pre}} \times 100 \%$$

By the same method, the volume reduction rate (VRR) was calculated as follows:

$$VRR = \frac{[GTV_{pre} - GTV_{dur}]}{GTV_{pre}} \times 100 \%$$

**Statistical Analysis**

Statistical analysis was performed using SPSS 21.0 software (IBM Corp, Armonk, NY, USA). Data with skewed distribution are presented as medians with ranges. The Wilcoxon signed-rank test was used to compare the target volumes and relevant parameters. Spearman’s rank correlation analysis was performed to analyze the relativity between SUVs and ADCs. A p-value <0.05 indicated statistical significance.

**RESULTS**

**Correlation Analysis of GTVs and GTV_{CT}**

The volume of GTV_{CT}^{pre} was 26.34 (4.50–118.71) cm³, leading to a significantly positive correlation with both GTV_{PET}^{pre} (Figure 1A) and GTV_{DWI}^{pre} (Figure 1D) (r = 0.763 and r = 0.809, both p < 0.001). The volume of GTV_{CT}^{dur} was 16.74 (2.92–
57.13 cm³ and exhibited a significant positive correlation with both GTV_{PET\_dur} (Figure 1B) and GTV_{DWI\_dur} (Figure 1E) ($r = 0.826$ and $r = 0.703$, both $p < 0.001$). Similarly, the relative changes in the volume of PET-CT and DW-MRI ($\Delta$GTV_{PET}, $\Delta$GTV_{DWI}) before and during RT demonstrated a significantly positive correlation with that of CT ($\Delta$GTV_{CT}) before and during RT ($r = 0.616$ and $r = 0.716$, both $p < 0.001$) (Figure 1).

SUV and ADC Values

Table 2 summarizes the results of SUVs (SUV_{max}, SUV_{mean}, and SUV_{peak}) and ADCs (ADC_{mean} and ADC_{min}) performed before and during RT. The differences in SUVs (SUV_{max}, SUV_{mean}, and SUV_{peak}), MTV, TLG, and ADCs (ADC_{mean} and ADC_{min}) values as determined on 18F-FDG PET-CT and DW-MRI before and during RT were significant (both $p < 0.001$). A trend toward lower SUV and higher ADC was observed during the treatment process.

### Correlation of ADC and SUV Values

The tumor ADC and SUV values before and during RT showed negligible correlations (pre-RT: SUV_{max} vs. ADC_{min} $r = -0.322$, $p = 0.072$; SUV_{max} vs. ADC_{mean} $r = -0.217$, $p = 0.232$; SUV_{mean} vs. ADC_{min} $r = -0.258$, $p = 0.153$; SUV_{mean} vs. ADC_{mean} $r = -0.256$, $p = 0.158$; dur-RT: SUV_{max} vs. ADC_{min} $r = -0.133$, $p = 0.496$; SUV_{max} vs. ADC_{mean} $r = -0.133$, $p = 0.496$; SUV_{mean} vs. ADC_{min} $r = -0.013$, $p = 0.944$; SUV_{mean} vs. ADC_{mean} $r = -0.121$, $p = 0.510$). There was no correlation between $\Delta$SUV values ($\Delta$SUV_{max}, $\Delta$SUV_{mean}, and $\Delta$SUV_{peak}) and $\Delta$ADC values ($\Delta$ADC_{min} and $\Delta$ADC_{mean}) ($p = 0.238–0.854$) (Table 3).

### Associations of SUVs and ADCs With Clinical Prognostic Factors

Table 4 shows associations of SUVs and ADCs with clinical T-stage and longitudinal length of GTVs. The SUVs (SUV_{max})...
SUV\textsubscript{mean} and SUV\textsubscript{peak}, MTV, and TLG pre-RT and its relative changes between pre-RT and after 15 fractions of RT were significantly higher in stages T3–4 than in stage T2 and in the group with a longitudinal length of GTVs ≥4 cm than <4 cm (p = 0.000–0.041). The ADC\textsubscript{min} dur-RT and its relative changes between pre-RT and after 15 fractions of RT were significantly lower in the group with a longitudinal length of GTVs ≥4 cm than <4 cm, but these were not significantly associated with clinical T-stage (Table 4).

### Differences in Volumes, CI, and DI

The target volumes defined using PET-CT and DW-MRI before and during RT are listed in Table 5. The median volume variations between GTV\textsubscript{PETpre} and GTV\textsubscript{DWIdur} and between GTV\textsubscript{PETdur} and GTV\textsubscript{DWIdur} were significant (p =0.026 and 0.000, respectively). Significant differences were observed between the CI of GTV\textsubscript{PETpre} to GTV\textsubscript{DWIdur} (0.47 [0.20–0.77]) and GTV\textsubscript{PETdur} to GTV\textsubscript{DWIdur} (0.29 [0.11–0.48]) (Z = −4.750, p < 0.001). Meanwhile, the DI of GTV\textsubscript{PETpre} in GTV\textsubscript{DWIdur} (0.63

### Table 3 | Correlation analysis of relative changes in SUV and ADC values before and during radiotherapy.

| Parameters | ΔSUV\textsubscript{max} | ΔADC\textsubscript{mean} | ΔSUV\textsubscript{peak} | ΔMTV | ΔTLG | ΔADC\textsubscript{min} | ΔADC\textsubscript{mean} |
|------------|------------------------|-------------------------|-------------------------|--------|--------|------------------------|-------------------------|
| r-value    | 1                      | 0.894                   | 0.833                   | 0.154  | 0.622  | −0.196                 | −0.087                 |
|            | <0.001                 | <0.001                 | <0.001                 | 0.238  | 0.635  |
| r-value    | 1                      | 0.870                   | 0.236                   | 0.715  | −0.179 | −0.035                 |
|            | <0.001                 | <0.001                 | <0.001                 | 0.327  | 0.848  |
| r-value    | 1                      | 0.0316                  | 0.0278                  | 0.044  | 0.854  |
|            | <0.001                 | <0.001                 | <0.001                 | 0.190  |
| r-value    | 1                      | 0.739                   | 0.253                   | −0.238 |
|            | <0.001                 | 0.163                   | 0.190                 |
| r-value    | 1                      | 0.179                   | 0.327                 |
|            | <0.001                 | 0.190                 |
| r-value    | 1                      | 1                      |
|            | <0.001                 | 0.190                 |

SUV\textsubscript{max}, maximum standardized uptake value; SUV\textsubscript{mean}, mean standardized uptake value; SUV\textsubscript{peak}, peak standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; ADC\textsubscript{mean}, the minimum apparent diffusion coefficient; ADC\textsubscript{mean}, the mean apparent diffusion coefficient.

### Table 4 | Associations of SUVs and ADCs with clinical T-stage and longitudinal length of GTVs.

| Parameters | Clinical T-stage | Longitudinal length of GTVs |
|------------|------------------|-----------------------------|
|             | ≤CT2 (n = 11)    | ≥CT3 (n = 21)               | <4 cm (n = 15)            | ≥4 cm (n = 17) |
|             | p-value          | p-value                     | p-value                   | p-value       |

#### Preradiotherapy PET(DWI)

| S\textsubscript{max}  | 7.67 [3.02–15.67] | 16.89 [10.75–22.94] | 0.001 |
| S\textsubscript{mean} | 4.02 [1.32–8.83]  | 9.21 [3.33–12.75]   | 0.000 |
| S\textsubscript{peak} | 5.86 [3.57–11.31] | 12.65 [8.69–19.34]  | 0.000 |
| MTV          | 7.99 [1.07–14.67] | 18.86 [2.11–90.50]  | 0.000 |
| TLG         | 24.89 [4.49–72.94] | 144.86 [26.93–833.1] | 0.000 |
| ADC\textsubscript{min} | 0.55 [0.30–1.04]  | 0.39 [0.31–0.63]    | 0.074 |
| ADC\textsubscript{mean} | 1.31 [0.92–1.52]  | 1.27 [1.07–1.83]    | 0.706 |

#### Dur-radiotherapy PET(DWI)

| S\textsubscript{max}  | 4.91 [1.74–13.69] | 10.46 [3.76–13.75] | 0.025 |
| S\textsubscript{mean} | 3.31 [2.14–8.04]  | 5.10 [2.43–7.33]   | 0.088 |
| S\textsubscript{peak} | 3.07 [2.03–6.53]  | 7.56 [3.20–11.10]  | 0.000 |
| MTV          | 4.45 [1.74–15.55] | 10.85 [2.13–54.38] | 0.077 |
| TLG         | 24.44 [9.72–45.56] | 53.84 [10.18–285.20] | 0.006 |
| ADC\textsubscript{min} | 0.92 [0.27–2.09]  | 0.67 [0.22–1.19]   | 0.131 |
| ADC\textsubscript{mean} | 2.42 [1.66–4.24]  | 2.23 [1.15–2.73]   | 0.706 |

#### Relative change from preradiotherapy PET(DWI)to dur-radiotherapy PET(DWI)

| ΔS\textsubscript{max} | 1.59 [−5.21–11.56] | 6.74 [0.21–15.45] | 0.010 |
| ΔS\textsubscript{mean} | 0.44 [−2.63–4.07]  | 2.90 [−0.39–9.7]  | 0.002 |
| ΔS\textsubscript{peak} | 3.11 [0.75–4.78]  | 5.36 [0.03–10.53] | 0.004 |
| ΔMTV          | −0.20 [−5.10–15.18] | 7.84 [−4.45–62.51] | 0.005 |
| ΔTLG         | 9.56 [−12.44–48.7] | 88.96 [4.06–721.10] | 0.000 |
| ΔADC\textsubscript{min} | 0.34 [−0.40–1.19]  | 0.30 [−0.37–0.56] | 0.525 |
| ΔADC\textsubscript{mean} | 0.99 [0.23–2.51]  | 0.75 [0.21–1.42] | 0.132 |

SUV\textsubscript{max}, maximum standardized uptake value; SUV\textsubscript{mean}, mean standardized uptake value; SUV\textsubscript{peak}, peak standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; ADC\textsubscript{min}, the minimum apparent diffusion coefficient; ADC\textsubscript{mean}, the mean apparent diffusion coefficient.
was significantly larger than that of GTV_{PET\text{dur}} in GTV_{DWI\text{dur}} (0.38 [0.11–0.92]) (Z = −4.675, p < 0.001).

**Tumor Maximum Diameter/Volume Shrinkage Rate**

There was no significant difference between LD_{PET\text{pre}} and LD_{DWI\text{pre}} and between LD_{PET\text{dur}} and LD_{DWI\text{dur}} (median 2.85 cm [1.48–6.31] vs. 2.92 cm [1.89–5.33], median 2.36 cm [1.47–4.79] vs. 2.22 cm [1.35–3.47], Z = −1.169 and −1.187, p = 0.243 and 0.235, respectively). There was a significant positive correlation between LD_{PET\text{pre}} and LD_{DWI\text{pre}} and between VRR_{PET} and VRR_{DWI} (r = 0.631 and 0.547, p = 0.000 and 0.001, respectively). \(△L_{DWI\text{pre}}\) (24%) and VRR_{DWI} (60%) based on DWI during RT were significantly greater than the corresponding PET-based \(△L_{PET\text{pre}}\) (14%) and VRR_{PET} (41%) (Z = −2.393 and −3.758, p = 0.017 and 0.000, respectively) (Figure 2).

**DISCUSSION**

In this single-center prospective study, comparisons of the spatial overlap and functional markers derived from 18F-FDG PET-CT and DW-MRI before and during RT based on the medium of CT imaging were evaluated. The results of the current study show that it is feasible to select boosting of high 18F-FDG uptake zones within the GTV based on FDG PET-CT for definition of the volume in need of dose escalation (4, 5, 23). However, owing to exorbitant costs and physical burden to patients undergoing repeated PET procedures, MRI-guided Linear Accelerator (MRI-LINAC) with online MR-guided adaptive radiotherapy (MRgRT) in EC has been widely applied (24). Furthermore, ADC measurements on DW-MRI have potential for prediction of response to treatment in esophageal cancer patients, especially the relative ADC increase during and after treatment showed a trend towards a larger increase of ADC in good responders compared with poor responders (16). Hence, we aimed to explore whether the high signal area derived from DW-MRI can be used as tool for an individualized definition of the volume in need of dose escalation for EC. To our knowledge, this is the first prospective trial assessing the geometrical differences and metabolic parameters between two imaging modalities in the reirradiation treatment planning for esophageal squamous cancer.

Currently, the method of gradient-based algorithm (PET\text{Edge}) has been found to correspond better to pathological specimens

**TABLE 5 | Summary of the volume of GTVs contoured using PET-CT and DW-MRI before and during radiotherapy.**

| Modality         | Target volumes | Z-value | p-value |
|------------------|----------------|---------|---------|
|                  | Median         | Range   |         |
|                  | Min            | Max     |         |
| GTV_{PET\text{pre}} | 13.77          | 1.07    | 90.50   | −2.225 | 0.026 |
| GTV_{DWI\text{pre}} | 12.16          | 4.74    | 46.86   | 0.000  | 0.000 |
| GTV_{PET\text{dur}} | 10.30          | 1.74    | 54.38   | −3.815 | 0.000 |
| GTV_{DWI\text{dur}} | 5.54           | 1.65    | 19.30   | 0.000  | 0.000 |

**FIGURE 2 | A transversal diagram of gross target volumes on esophageal cancer with high uptake on 18F fluorodeoxyglucose positron emission tomography/computed tomography fused images.** (A,a) Corresponding tumor on T2-weighted imaging (C,c) with a high signal on diffusion weighted magnetic resonance imaging (b=600 s/mm²) (B,b) and corresponding apparent diffusion coefficient map (D,d) with restricted diffusion at the location of the tumor before radiotherapy (A–D) and during radiotherapy (a–d).
than manual or relative threshold-based methods (19). However, no single PET-based segmentation algorithm has yet performed better than manual CT delineation alone (16), implying that PET-guided adaptive radiotherapy was insufficient for clinical decision-making. Till date, CT imaging remains the gold standard for GTV delineation and treatment planning. On this basis, our data suggest that the volume of GTV_{CT} exhibited a significant positive correlation with that of GTV_{PET} and GTV_{DWI}.

Based on our analysis, the results showed that the differences in SUV and ADC values before and during RT were significant, consistent with the findings of more recent studies (25, 26). There is also clear evidence that higher SUV and lower ADC values are associated with a higher histological grade and aggressiveness (17, 27). With high cellular density and enhanced glucose metabolism, malignant tumors generally exhibit low ADCs and high SUVs. Several studies indicate that the change in tumor $^{18}$F-FDG uptake for EC seemed highly correlated with that of ADCs and SUVs before and during RT showed negligible underestimation of the FDG uptake observed on midtreatment PET scan. As a result, selective boosting of high $^{18}$F-FDG uptake zones within the tumor for radioresistance has been suggested. However, part of the limitations of PET can be attributed to the fact that no consensus for the accurate segmentation algorithm is required. Meanwhile, DW-MRI is emerging as an advanced imaging technique with noninvasive, well-tolerated, and excellent soft-tissue contrast features for diagnosing EC. ADC value is the most common DWI-derived imaging biomarker with broad clinical applications. More importantly, recent exploratory studies have shown that changes in ADC appear to provide valuable information on the prediction and assessment of treatment response early after RT (7, 16, 17). Consequently, regions of restricted diffusion may serve as a surrogate for active tumor tissue. DW-MRI may be a technically and clinically available alternative to PET-CT for an individualized definition of the volume in need of dose escalation for EC.

Concerning the possible correlation between ADCs and SUVs for the prediction of survival or evaluation of response to treatment in EC, our current data suggest that the tumor ADCs and SUVs before and during RT showed negligible correlations. Similar to our findings, previous studies also found no significant correlations between pretreatment SUVs and ADCs (30–32). Our results also revealed that pretreatment SUVs, MTV, and TLG were significantly higher in tumor stage $\geq$ T$_3$ than in tumor stage $<$ T$_2$, while ADC$_{\text{min}}$ values has not yet been found to correlate with the clinical T-stage, indicating the effect of tumor load on $^{18}$F-FDG metabolism, consistent with the literature (8, 33). These results suggest that enhanced glucose metabolism as measured on FDG PET and restricted water diffusion as measured using ADC represent independent biological properties and refer to different aspects of tumor pathophysiology. This is likely owing to the variety of pathogenic mechanisms because of which elevated $^{18}$F-FDG uptake was detected in the sites of glucose metabolism and active inflammation, while no significant changes in cell density were detected in the activity of inflammatory cells (28, 33, 34). Additionally, necrosis and liquefaciens induced by radiation can impede movement of water molecules, leading to increased ADC values. Finally, it is likely that the timing and distribution of decreased glucose metabolism and cellular density are asynchronous and inconsistent.

In addition, we evaluated the difference in matching and inclusion relation between the GTVs derived from PET-CT and DW-MRI simulation before and during RT. Our results indicate that the CI of GTV_{PETpre} to GTV_{DWIpre} was significantly larger than that of GTV_{PETdur} to GTV_{DWIdur}. Meanwhile, a significant difference was observed between the DI of GTV_{PETpre} in GTV_{DWIpre} and GTV_{PETdur} in GTV_{DWIdur}. Our study results are also consistent with the findings of Popp et al. (34) and Houweling et al. (35), who showed that the GTV of restricted diffusion on ADC overlapped only partially with that of increased glucose uptake for reirradiation treatment planning, suggesting that there were great mismatches between the regions of residual high FDG uptake based on PET-CT and the areas of residual high signal based on DW-MRI. Moreover, given the data from our study, the rate of tumor maximum diameter/volume regression based on DW-MRI during RT is significantly faster than that based on PET-CT. This suggests that the regions of high cellularity may not cover the entire biologically active tumor, agreeing with earlier studies comparing DWI and PET in reirradiation of recurrent primary brain tumors (34, 35).

Some limitations of the current study must be considered. A potential disadvantage of EPI-DWI is that the technique is prone to artifact contamination caused by variations in magnetic susceptibility (36). To minimize this, the study excluded some cases with a small volume and severe image distortions. Additionally, The magnitude of the geometric distortion scales with magnetic field strength (37). Considering that the use of 3.0 T MRI was applied, the limitation of the geometric distortion caused by high field strength must be considered. Owing to the partial-volume and pseudo-diffusion effect caused by tumor vascular permeability and microcirculation perfusion, tumor shrinkage upon initiation of treatment may lead to underestimation of the FDG uptake observed on midtreatment imaging modalities and a consequent overestimation of the change in parameters such as the SUV. Further dosimetric investigations are necessary to evaluate whether it is safe to select boosting of the high signal areas within the tumor based on DW-MRI for definition of the volume in need of dose escalation.

CONCLUSIONS

The location of high residual FDG uptake based on $^{18}$F-FDG PET-CT yielded poorer spatial matching than that of high residual signal based on DW-MRI during RT. Furthermore, tumor ADC and SUV values may play complementary roles as imaging markers for the prediction of patterns of failure and for definition of the volume in need of dose escalation. In addition, the rate of tumor maximum diameter/volume regression based
on DW-MRI during RT is significantly faster than that based on PET-CT. Based on the medium of CT images, the volume of GTV\textsubscript{CT} exhibited a significant positive correlation with that of GTV\textsubscript{PET} and GTV\textsubscript{DWI}. Under this premise, there are significant differences in spatial position, biometabolic characteristics, and the tumor shrinkage rate for GTVs derived from \textsuperscript{18}F-FDG PET-CT and DW-MRI before and during RT for esophageal squamous cancer. Further studies are needed to determine if DW-MRI will be used as tool for an individualized definition of the volume in need of dose escalation.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Shandong Tumor Hospital Ethics Committee. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**REFERENCES**

1. Kakeji Y, Oshikiri T, Takiguchi G, Kanaji S, Matsuda T, Nakamura T, et al. Multimodality Approaches to Control Esophageal Cancer: Development of Chemoradiotherapy, Chemotherapy, and Immunotherapy. *Esophagus* (2021) 18(1):25–32. doi: 10.1007/s10388-020-00782-1
2. Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD. Study to Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by Detailing Patterns of Recurrence After Definitive Chemoradiotherapy. *Int J Radiat Oncol Biol Phys* (2009) 73(3):818–23. doi: 10.1016/j.ijrobp.2008.04.062
3. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, et al. Failure Patterns in Patients With Esophageal Cancer Treated With Definitive Chemoradiation. *Cancer* (2012) 118(10):2632–40. doi: 10.1002/cncr.26586
4. Grover A, Soni TP, Patni N, Singh DK, Jakhodia N, Gupta AK, et al. A Randomized Prospective Study Comparing Acute Toxicity, Compliance and Objective Response Rate Between Simultaneous Integrated Boost and Sequential Intensity-Modulated Radiotherapy for Locally Advanced Head and Neck Cancer. *Radiat Oncol J* (2021) 39(1):15–23. doi: 10.3857/roj.2020.01018
5. Yu W, Cai XW, Liu Q, Zhu ZF, Feng W, Zhang Q, et al. Safety of Dose Escalation by Simultaneous Integrated Boosting Radiation Dose Within the Primary Tumor Guided by (18)FDG-PET/CT for Esophageal Cancer. *Radiother Oncol* (2015) 114(2):195–200. doi: 10.1016/j.radonc.2014.12.007
6. Kim N, Cho H, Yun M, Park KR, Lee CG. Prognostic Values of Mid-Radiotherapy \textsuperscript{18}F-FDG PET/CT in Patients With Esophageal Cancer. *Radiol Oncol* (2019) 54(1):27. doi: 10.1186/s13014-019-1232-1
7. Borgegreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JFW, et al. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using \textsuperscript{18}F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study. *Int J Radiat Oncol Biol Phys* (2020) 106(5):998–1009. doi: 10.1016/j.ijrobp.2019.12.038
8. Yu CW, Chen XL, Lin YH, Tseng YH, Lu CC, Chen BR, et al. Prognostic Value of \textsuperscript{18}F-FDG PET/CT/MR Imaging Biomarkers in Oesophageal Squamous Cell Carcinoma. *Eur J Radiol* (2019) 120:108671. doi: 10.1016/j.ejrad.2019.108671
9. Chang S, Kim SJ. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters. *Cancer Biother Radiopharm* (2016) 31(1):1–6. doi: 10.1089/cbr.2015.1932
10. Minsky BD, Pajak TF, Ginsberg R, Pisansky TM, Martenson J, Komaki R, et al. Int 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy. *J Clin Oncol Radiat Ther Oncol Group* (2002) 20(5):1167–74. doi: 10.1200/JCO.2002.20.5.1167
11. Calais J, Dubray B, Nkali L, Thureau S, Lemagninier C, Modzelewski R, et al. High FDG Uptake Areas on Pre-Radiotherapy PET/CT Identify Preferential Sites of Local Relapse After Chemoradiotherapy for Locally Advanced Oesophageal Cancer. *Eur J Nucl Med Mol Imaging* (2015) 42(6):858–67. doi: 10.1007/s00259-015-3004-y
12. Huang B, Law MW, Khong PL. Whole-Body PET/CT Scanning: Estimation of Radiation Dose and Cancer Risk. *Radiology* (2009) 251(1):166–74. doi: 10.1148/radiol.2511081300
13. Cremonesi M, Garibaldi C, Timmerman R, Ferrari M, Ronchi S, Grana CM, et al. Interim \textsuperscript{18}F-FDG-PET/CT During Chemo-Radiotherapy in the Management of Oesophageal Cancer Patients. *A Syst Rev Radiother Oncol Radiother Oncol* (2017) 125(2):200–12. doi: 10.1016/j.radonc.2017.09.022
14. Goense L, Borggreve AS, Heethuis SE, van Lier AL, van Hillegersberg R, Mook S, et al. Patient Perspectives on Repeated MRI and PET/CT Examinations During Neoadjuvant Treatment of Esophageal Cancer. *Br J Radiol* (2018) 91(1086):20170710. doi: 10.1259/bjr/20170710
15. Li H, Li L, Li F, Li J, Zhu Y, Zhang Y, Guo Y, et al. Comparison of Gross Target Volumes Based on Four-Dimensional CT, Positron Emission Tomography-Computed Tomography, and Magnetic Resonance Imaging in Thoracic Esophageal Cancer. *Cancer Med* (2020) 9(15):5353–61. doi: 10.1002/cam4.3072
16. Vollenbrock SE, Voncken FEM, Bartels LW, Beets-Tan RGH, Bartels-Rutten A. Diffusion-Weighted MRI With ADC Mapping for Response Prediction and Assessment of Esophageal Cancer: A Systematic Review. *Radiother Oncol* (2020) 142:17–26. doi: 10.1016/j.radonc.2019.07.006
17. Giganzi F, Salerno A, Ambrosi A, Chiari D, Orsengo E, Esposito A, et al. Prognostic Utility of Diffusion-Weighted MRI in Oesophageal Cancer: Is Apparent Diffusion Coefficient a Potential Marker of Tumour Aggressiveness? *Radiol Med* (2016) 121(3):173–80. doi: 10.1007/s11547-015-0585-2
18. Lever FM, Lips IM, Crijns SP, Reerink O, van Lier AL, Meoeland MA, et al. Quantification of Esophageal Tumor Motion on Cine-Magnetic Resonance Imaging. *Int J Radiat Oncol Biol Phys* (2014) 88(2):214–24. doi: 10.1016/j.ijrobp.2013.10.036
19. Werner-Wasik M, Nelson AD, Choi W, Aral Y, Faulhaber PF, Kang P, et al. What is the Best Way to Contour Lung Tumors on PET Scans? Multiobserver Validation of a Gradient-Based Method Using a NSCLC Digital PET Phantom. *Int J Radiat Oncol Biol Phys* (2012) 82(3):1164–71. doi: 10.1016/j.ijrobp.2010.12.055
20. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. *Clin Positron Imaging* (1999) 2(3):159–71. doi: 10.1097/000903799900163-3
21. Struikmans H, Wârlam-Rodenhuis C, Stam T, Stapper G, Tersteg RJ, Bol GH, et al. Interobserver Variability of Clinical Target Volume Delineation of Glandular Breast Tissue and of Boost Volume in Tangential Breast Irradiation. *Radiother Oncol* (2005) 76(3):293–9. doi: 10.1016/j.radonc.2005.03.029
22. HoY, Rhein B, Haering P, Kopp-Schneider A, Debus J, Herfarth K. 4d-CT-Based Target Volume Definition in Stereotactic Radiotherapy of Lung Tumours: Comparison With a Conventional Technique Using Individual Margins. *Radiother Oncol* (2009) 93(3):419–23. doi: 10.1016/j.radonc.2009.08.040
23. Nakhal I, Thureau S, Edet-Sanson A, Doyeux K, Benyoucef A, Gardin I, et al. FDG-PET/CT During Concomitant Chemotherapy for Esophageal Cancer: Reducing Target Volumes to Deliver Higher Radiotherapy Doses. *Acta Oncol* (2015) 54(6):909–15. doi: 10.3109/0284186X.2014.973602
24. Boekhoff MR, Defze IL, Borggreve AS, Takahashi N, van Lier ALHMW, Ruurda JP, et al. 3-Dimensional Target Coverage Assessment for MRI Guided Esophageal Cancer Radiotherapy. *Radiother Oncol* (2020) 147:1–7. doi: 10.1016/j.radonc.2020.03.007
25. Heijmen L, ter Voert EE, Oyen WJ, Punt CJ, van Sproons DJ, Heerschap A, et al. Multimodality Imaging to Predict Response to Systemic Treatment in Patients With Advanced Colorectal Cancer. *PloS One* (2015) 10(4):e0120823. doi: 10.1371/journal.pone.0120823
26. Weber MA, Bender K, von Gall CC, Stange A, Grünberg K, Ott K, et al. Assessment of Diffusion-Weighted MRI and 18F-Fluoro-Deoxyglucose PET/CT in Monitoring Early Response to Neoadjuvant Chemotherapy in Adenocarcinoma of the Esophagogastric Junction. *J Gastrointestin Liver Dis* (2013) 22(1):45–52.
27. Shimizu D, Yuasa N, Miyake H, Takeuchi E, Miyata K, Itoh S. Clinical Significance of SUVmax on Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients Who Underwent R0-Esophagectomy for Esophageal Cancer. *Nagoya J Med Sci* (2018) 80(3):401–9. doi: 10.18999/nagims.80.3.401
28. Unterrainer M, Eze C, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, et al. Recent Advances of PET Imaging in Clinical Radiation Oncology. *Rad Oncol* (2020) 15(1):88. doi: 10.1186/s13014-020-01519-1
29. Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Looij Jv, Houben R, et al. Identification of Residual Metabolic-Active Areas Within Individual NSCLC Tumours Using a Pre-Radiotherapy (18)F-luoro-L-Dopa and PET-CT Scan. *Radiother Oncol* (2009) 91(3):386–92. doi: 10.1016/j.radonc.2009.03.006
30. Varoquaux A, Rager O, Lovblad KO, Masterson K, Dulguerov P, Batih O, et al. Functional Imaging of Head and Neck Squamous Cell Carcinoma With Diffusion-Weighted MRI and FDG PET/CT: Quantitative Analysis of ADC and SUV. *Eur J Nucl Med Mol Imaging* (2013) 40(6):842–52. doi: 10.1007/s00259-013-2351-9
31. Goense L, Heethuis SE, van Rossum PSN, Voncken FEM, Lagendijk JJW, Lam MGEH, et al. Correlation Between Functional Imaging Markers Derived From Diffusion-Weighted MRI and 18F-FDG PET/CT in Esophageal Cancer. *Nucl Med Commun* (2018) 39(1):60–7. doi: 10.1097/NMM. 0000000000000771
32. de Jong A, Kwie TC, de Klerk JM, Adam JA, de Keizer B, Fijnheer R, et al. Relationship Between Pretreatment FDG-PET and Diffusion-Weighted MRI Biomarkers in Diffuse Large B-Cell Lymphoma. *Am J Nucl Med Mol Imaging* (2014) 4(3):231–8.
33. Qu YH, Long N, Ran C, Sun J. The Correlation of 18F-FDG PET/CT Metabolic Parameters, Clinicopathological Factors, and Prognosis in Breast Cancer. *Clin Transl Oncol* (2021) 23(6):620–7. doi: 10.1007/s12094-020-02457-w
34. Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, et al. Diffusion-Weighted MRI and ADC Versus PET-FET and GdT1w-MRI for Gross Tumor Volume (GTV) Delineation in Re-Irradiation of Recurrent Glioblastoma. *Radiother Oncol* (2019) 130:121–31. doi: 10.1016/j.radonc.2018.08.019
35. Houweling AC, Wolf AL, Vogel WV, Hamming-Vrieze O, van Vliet-Vregouwdeiwe C, van de Kamer JB, et al. FDG-PET and Diffusion-Weighted MRI in Head-and-Neck Cancer Patients: Implications for Dose Painting. *Radiother Oncol* (2013) 106(2):250–4. doi: 10.1016/j.radonc.2013.01.003
36. Min LA, Vacher YJL, Dewit L, Donker M, Sofia C, van Triest B, et al. Gross Tumour Volume Delineation in Anal Cancer on T2-Weighted and Diffusion-Weighted MRI – Reproducibility Between Radiologists and Radiation Oncologists and Impact of Reader Experience Level and DWI Image Quality. *Radiother Oncol* (2020) 150:81–8. doi: 10.1016/j.radonc.2020.06.011
37. Weygang J, Fuller CD, Ibbott GS, Mohamed AS, Ding Y, Yang J, et al. Spatial Precision in Magnetic Resonance Imaging-Guided Radiation Therapy: The Role of Geometric Distortion. *Int J Radiat Oncol Biol Phys* (2016) 95(4):1304–16. doi: 10.1016/j.ijrobp.2016.02.059

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Li, Li, Li, Zhang, Li, Guo and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.